Advertisement

Onglyza® (saxagliptin) is the third drug in a new class of oral diabetes medications, called DPP-4 inhibitors. It was approved for sale in the United States July 31, 2009. It will probably be available in Europe soon.

saxagliptin

• Brand name in US: Onglyza®
• Class: DPP-4 inhibitor
• For: Type 2 diabetes
• Route of Administration: oral
• Action: inhibits DPP-4 (dipeptidyl peptidase-4), allowing potentiation of the secretion of insulin by beta cells.
• Manufacturer: Bristol-Myers Squibb in collaboration with AstraZenaca
• Status: Approved in the US July 31, 2009. EMEA approval June, 2009; anticipated launch in Germany in the third quarter of 2009.
• Sources: Press release from manufacturer: U.S. Food and Drug Administration Approves ONGLYZA™ (saxagliptin) for the Treatment of Type 2 Diabetes Mellitus in Adults; news story AstraZeneca, Bristol-Myers Prepare for German Onglyza Start
• Other drugs in the same class: Januvia (sitagliptin) (approved in US and Europe); Galvus (vitagliptin) (approved in Europe; undergoing FDA review as of August 2009).

Also see

Saxagliptin At Wikipedia.

Onglyza from the manufacturer.